Genetic basis for personalized medicine in asthma

There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic receptor agonists, corticosteroids and leukotriene m...

Full description

Bibliographic Details
Main Authors: Portelli, Michael A., Sayers, Ian
Format: Article
Published: Expert Reviews 2012
Online Access:https://eprints.nottingham.ac.uk/2688/
_version_ 1848790850111275008
author Portelli, Michael A.
Sayers, Ian
author_facet Portelli, Michael A.
Sayers, Ian
author_sort Portelli, Michael A.
building Nottingham Research Data Repository
collection Online Access
description There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets.
first_indexed 2025-11-14T18:19:10Z
format Article
id nottingham-2688
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:19:10Z
publishDate 2012
publisher Expert Reviews
recordtype eprints
repository_type Digital Repository
spelling nottingham-26882020-05-04T20:21:43Z https://eprints.nottingham.ac.uk/2688/ Genetic basis for personalized medicine in asthma Portelli, Michael A. Sayers, Ian There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets. Expert Reviews 2012-04 Article PeerReviewed Portelli, Michael A. and Sayers, Ian (2012) Genetic basis for personalized medicine in asthma. Expert Review of Respiratory Medicine, 6 (2). pp. 223-236. ISSN 1747-6348 http://www.expert-reviews.com/doi/abs/10.1586/ers.12.9 doi:10.1586/ers.12.9 doi:10.1586/ers.12.9
spellingShingle Portelli, Michael A.
Sayers, Ian
Genetic basis for personalized medicine in asthma
title Genetic basis for personalized medicine in asthma
title_full Genetic basis for personalized medicine in asthma
title_fullStr Genetic basis for personalized medicine in asthma
title_full_unstemmed Genetic basis for personalized medicine in asthma
title_short Genetic basis for personalized medicine in asthma
title_sort genetic basis for personalized medicine in asthma
url https://eprints.nottingham.ac.uk/2688/
https://eprints.nottingham.ac.uk/2688/
https://eprints.nottingham.ac.uk/2688/